Updated BioRestorative (NASDAQ: BRTX) investor deck for conferences
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
BioRestorative Therapies, Inc. furnished an updated corporate presentation that may be used at conferences and investor meetings. The deck is available on the company’s website and is attached as Exhibit 99.1.
The presentation is furnished under a disclosure item and is not deemed filed or subject to Section 18 liability, nor automatically incorporated into other Securities Act or Exchange Act filings.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
emerging growth company, Section 18 of the Securities Exchange Act of 1934, furnished, not filed, Inline XBRL
4 terms
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 18 of the Securities Exchange Act of 1934 regulatory
"will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934"
furnished, not filed regulatory
"The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01."
Inline XBRL technical
"104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
___________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: April 23, 2026
(Date of earliest event reported)
(Exact Name of Registrant as Specified in Charter)
| | | |
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification Number) |
| | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (631 ) 760-8100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| | | |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ____
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
|
Item 7.01
|
Regulation FD Disclosure.
|
On April 23, 2026, BioRestorative Therapies, Inc. (the “Company”) made available an updated corporate presentation (the “Presentation”) that may be used by the Company in connection with presentations at conferences and investor meetings. The Presentation can be found on the Company’s website, www.biorestorative.com. The Presentation is furnished as Exhibit 99.1 hereto.
The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
Exhibits.
|
Number
|
Description
|
|
|
|
|
99.1
|
Presentation Materials
|
|
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: April 23, 2026
|
BIORESTORATIVE THERAPIES, INC.
|
|
|
|
|
|
By: /s/ Robert Kristal
|
|
|
Robert Kristal
|
|
|
Chief Financial Officer
|
FAQ
What did BioRestorative Therapies (BRTX) disclose in this 8-K?
BioRestorative Therapies disclosed that it has made an updated corporate presentation available. The presentation may be used at conferences and investor meetings, is posted on the company’s website, and is included with the filing as Exhibit 99.1 for informational purposes.
Where can investors find BioRestorative Therapies’ updated corporate presentation?
The updated corporate presentation is available on BioRestorative Therapies’ website at www.biorestorative.com. It is also attached to the SEC report as Exhibit 99.1, allowing investors to review the same materials used in conferences and investor meetings.
Is the BioRestorative Therapies investor presentation considered filed with the SEC?
No. The company states the presentation is being furnished, not filed. That means it is not deemed filed for purposes of Section 18 of the Exchange Act and is not automatically incorporated into other Securities Act or Exchange Act filings by the company.
Does BioRestorative consider the updated presentation to be material information?
The company explicitly notes the furnishing of the presentation is not an admission that the information is material or complete. It also states that investors should not assume the presentation alone is sufficient for making an investment decision regarding its securities.
What exhibit numbers are included with this BioRestorative Therapies report?
The report lists Exhibit 99.1 for the presentation materials and Exhibit 104 for the cover page interactive data file embedded within the Inline XBRL document. These exhibits package the investor deck and the required structured data for electronic reporting.